Application: Traitement du psoriasis en plaques, du rhumatisme psoriasique et de la maladie de Behçet (inhibiteur de la PDE4)
IUPAC Name: N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide
EC Number: 807-237-6
Molecular Weight: 460.5
Chemical Formula: C₂₂H₂₄N₂O₇S
CAS Number: 608141-41-9
Type de formulation: Solide cristallin, forme B (polymorphe)
Statut réglementaire: Approuvé par la FDA pour le rhumatisme psoriasique, le psoriasis en plaques et la maladie de Behçet
Status: Pipeline
Therapeutic cat.: Musculo-skeletal
Polymorphic form: Form B

Autres informations

Description supplémentaire:

Manufactured directly by Polpharma, this Apremilast (CAS 608141-41-9, Polymorphic Form B) is the active ingredient behind Otezla, a PDE4 inhibitor used to treat plaque psoriasis, psoriatic arthritis, and Behçet's disease by raising intracellular cAMP levels to reduce inflammation; it is FDA-approved and not yet available generically. Polpharma notes EU, US, and Canadian DMF readiness, and its listing carries a disclaimer that certain SPC-protected products from the company are produced solely for regulatory/R&D purposes or for export to non-EU markets where patent protection does not apply. It is distributed globally across the Americas, Europe, Australasia, Asia, the Middle East, and Africa.